LUXEMBOURG INSTITUTE OF HEALTH

Their core work

LIH is a biomedical research institute focused on discovering and validating biomarkers for disease diagnosis, prognosis, and treatment stratification. Their core work spans immunology, microbiome research, and translational medicine — turning molecular findings into clinically useful diagnostic tools. They are particularly active in cancer immunoprofiling, cardiovascular biomarkers, and inflammatory bowel diseases. LIH also contributes to large European health data infrastructures and personalized medicine standardization efforts.

What they specialise in

How they've shifted over time

In 2016–2018, LIH focused on human biomonitoring, environmental exposure biomarkers, and clinical trial infrastructure — working as a third party in large clinical networks (HBM4EU, HIVACAR, PedCRIN). From 2019 onward, the institute shifted decisively toward cancer immunoprofiling, personalized medicine, and AI-assisted diagnostics, while also stepping up as project coordinator. The COVID-19 pandemic triggered a rapid pivot into RNA-based diagnostic biomarkers (COVIRNA), demonstrating their ability to deploy molecular expertise in response to urgent health crises.

LIH is moving from supporting clinical infrastructure as a third party toward leading its own translational research programs in cancer immunology, microbiome science, and AI-driven biomarker diagnostics.

How they like to work

LIH operates as a flexible partner, contributing specialized biomarker and immunology expertise across a wide range of consortium sizes. With 13 projects as participant, 6 as third party, and 5 as coordinator, they have progressively taken on more leadership — all 5 coordinated projects fall in 2020–2021, signaling growing institutional ambition. Their network of 480 partners across 44 countries makes them a well-connected node in European health research, comfortable in both large multi-site clinical studies and focused MSCA fellowships.

LIH has collaborated with 480 unique partners across 44 countries, giving them one of the broadest networks for a mid-sized research institute. Their connections span clinical trial networks, large research infrastructures (EATRIS, EPND), and focused bilateral research fellowships.

What sets them apart

As Luxembourg's dedicated public health research institute, LIH occupies a rare position: small enough to be agile and responsive (demonstrated by their rapid COVID-19 pivot), yet embedded in one of Europe's most internationally connected research ecosystems. Their strength lies in bridging molecular biology and clinical application — they don't just discover biomarkers, they validate them for diagnostic use and contribute to standardization frameworks. For consortium builders, LIH brings strong translational capabilities without the bureaucratic overhead of a large university hospital.

Highlights from their portfolio

• IMMUcan
  Largest project by far (EUR 2.7M), focused on integrated immunoprofiling across five cancer types — positions LIH at the center of European cancer immunology.
• COVIRNA
  Coordinated by LIH, developed RNA-based diagnostic biomarkers for COVID-19 prognosis — demonstrates their ability to rapidly translate molecular expertise into clinical diagnostics.
• ORCHESTRA
  Second-largest funding (EUR 932K), connecting European COVID-19 cohorts — shows LIH's capacity to handle large-scale population health data.